A study published in 2020 used PDOs derived from SCLC patient tumors to develope a novel CDK7 inhibitor, YPN-005, which showed potent anticancer effects compared to the CDK7 inhibitor THZ1 (Choi Y. J. et al., 2021). Here, CDK7 is linked to small cell lung carcinoma.